A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Official Title

A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers


This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

Trial Description

Primary Outcome:

  • Percentage of Participants with Adverse Events
Secondary Outcome:
  • Serum Concentration of Runimotamab
  • Area Under the Serum Concentration vs. Time Curve (AUC) of Runimotamab
  • Maximum Observed Serum Concentration (Cmax) of Runimotamab
  • Minimum Observed Serum Concentration (Cmin) of Runimotamab
  • Clearance (CL) of Runimotamab
  • Volume of Distribution at Steady State (Vss) of Runimotamab
  • Objective Response (OR) as Determined by the Investigator According to Response Evaluation Criteria In Solid Tumours v1.1 (RECIST v1.1)
  • Duration of Response (DOR)
  • Anti-Drug Antibody (ADA) Levels of Runimotamab

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society